Just Like France Belgium disagrees with EMA and will veto against Finasteride Finasteride/Dutasteride 6/13/2025
Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.
View this post in the Community →
Similar Community Posts Join
5 / 1000+ resultscommunity Popular hair loss drug linked to higher suicide risk: compared to non-users, finasteride (Proscar/ Propecia) users have a markedly increased risk of depression, anxiety, and suicidal thoughts. Over 30 years of observation, 19,320 suicides were expected.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
community Publication concludes finasteride is a associated with a 60% risk of persistent sexual dysfunction.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
community Finasteride - impact on Neurosteroids, which yes, \are important and not a garbage hormone
Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.
community Cure/better treatment options in the future
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
Related Research
6 / 1000+ results
research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
Finasteride use may increase suicidality risk, especially in young men.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Farmácia Militar do Laboratório Nacional do Medicamento, Porto e Serviços Farmacêuticos do Centro Hospitalar Universitário do Porto (Hospital de Santo António), EPE, Porto
Pharmacists play a crucial role in patient care and optimizing treatment outcomes.
research Interventions for female pattern hair loss
Topical minoxidil helps treat female pattern hair loss, but more research needed for other treatments.
research 26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action
Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
research Nanotechnology-Based Strategies for Hair Regeneration: Mechanistic Insights and Translational Perspectives for Androgenetic Alopecia
Nanotechnology shows promise for treating hair loss but faces safety and approval challenges.